Moss cells engineered to produce anticancer drug

Scientists used Physcomitrium patens to create a stable way to make paclitaxel.

Researchers engineered a line of moss called Physcomitrium patens to produce paclitaxel. This is a valuable diterpenoid anticancer drug.

The drug was originally extracted from the yew tree. Extraction from plants has low efficiency and semi-synthesis is expensive.

The team used a modular iterative transformation strategy for stable genetic inheritance. This strategy allows for stable genetic inheritance. They also used a self-cleaving 2 A peptide-mediated multi-gene co-expression system. This system allows for multi-gene co-expression.

They combined cytoplasmic localization strategies with transient expression verification. Cytoplasmic localization strategies were used during the process. The engineered lines produced paclitaxel stably even after continuous subculturing multiple times.

This study proposes that Physcomitrium patens can serve as a plant chassis for paclitaxel biosynthesis. A plant chassis is the cell type used for biosynthesis.

Key facts

  • Paclitaxel is a diterpenoid anticancer drug originally from the yew tree.
  • Physcomitrium patens was engineered to produce paclitaxel through de novo and stable biosynthesis.
  • The engineered moss lines produced paclitaxel stably after multiple subculturing cycles.

All sections

Edition